Skip to main content

Jefferies Sticks to Their Buy Rating for Lantheus (LNTH)

Tipranks - Tipranks - Tue Nov 25, 2025

In a report released today, Matthew Taylor from Jefferies maintained a Buy rating on Lantheus, with a price target of $105.00.

TipRanks Black Friday Sale

Taylor covers the Healthcare sector, focusing on stocks such as Boston Scientific, Insulet, and Globus Medical. According to TipRanks, Taylor has an average return of 7.7% and a 55.71% success rate on recommended stocks.

Currently, the analyst consensus on Lantheus is a Moderate Buy with an average price target of $77.83.

See Insiders’ Hot Stocks on TipRanks >>

Based on Lantheus’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $384.01 million and a net profit of $27.77 million. In comparison, last year the company earned a revenue of $378.73 million and had a net profit of $131.09 million

Read More on LNTH:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).